General discussion, page-10594

TV - thank you: always a pleasure to see the good Dr Sud.
Harambe, the following article should be an interesting read for you: a recent University of Sydney study of THC intoxication duration.

https://www.sydney.edu.au/news-opinion/news/2021/04/12/scientists-put-stopwatch-on-cannabis-thc-intoxication-lambert-drug-driving.html

Of note, the medium dose in the study of 10mg corresponds to the highest of three doses Incannex planned for its soon-to-be-completed IHL-42x phase 2 trial. Our trial's lowest dose of Dronabinol (synthetic THC) is 2.5mg, just one quarter of the University of Sydney's medium dose.

We don't know how this study might influence laws in Australia and beyond, but one thing is certain: those who conducted it are explicit that the results are pertinent to any review of drug driving laws. One can be fairly certain these reviews will take place before too long, with the expansion of legal cannabinoid use around the world. Good to know the data is already there to guide them.

IHL-42x, taken more than 8 hours prior to a morning drive (so say before 11.30pm), should leave no relevant impairment at the 2.5mg and 5mg tested dosage levels. Let's hope these prove sufficient for desired efficacy. At 10mg, we might be straddling the threshold of where law-makers decide to draw the line, and the dose may need to be taken a full 10 hours prior... but it is impossible to know, and this is just me making semi-educated guesses based on what we know now.

Everything is a trade off: patients with moderate OSA may need to sacrifice some of their driving schedule flexibility in order to take the higher dose (if that higher dose even ends up being deemed useful once trials are completed), or opt for a lower dose, less relief, but zero compromising of how early in the morning they can jump behind the wheel. For patients with mild OSA, it looks like there might be no need to compromise at all.

Dr Sud sounds confident that they have struck a balance that removes impairment as a concern, so this may indicate that they have found 2.5mg and 5mg doses to be sufficient, and have included the higher 10mg dose in the phase 2 study to map that upper boundary rather than to include it as a prospective commercial dosage.

Good luck to all: I can't wait to sift through the results of the trial... only a few weeks to go!